Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.83 |
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.83 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.83 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4431832 | 1.00 | ADORA2A (0.83) | ADORA2AADORA3ADORA2BADORA1 | |
| Trifluoroacetic Acid SCHEMBL1412270 | 0.95 | ADORA2A (0.79) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL242090 | 0.90 | ADORA2A (0.85) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4371641 | 0.90 | ADORA2A (0.83) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5723583 | 0.90 | ADORA2A (0.83) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4371630 | 0.90 | ADORA2A (0.83) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL6835812 | 0.90 | ADORA2A (0.80) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL5411319 | 0.89 | ADORA2A (0.81) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4368838 | 0.89 | ADORA2A (0.81) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4368841 | 0.89 | ADORA2A (0.81) | ADORA2AADORA3ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5401378-A | ELECTRODE MEMBRANES FOR USE IN BIOSENSORS | AUSTRALIAN MEMBRANE & BIOTECHNOLOGY RESEARCH INSTITUTE (AU) | 1995-03-28 | — | — | US | claimed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| EP-2018381-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| EP-2013211-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| EP-1861412-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007121918-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| EP-0680488-B1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LTD (GB) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996002553-A2 | AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1996-02-01 | — | — | WO | disclosed |
| EP-0680488-A1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1995-11-08 | — | — | EP | disclosed |
| WO-1994017090-A1 | 2,6-DIAMINOPURINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1994-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA2B 4/4885 |
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885ADORA2B 1829/4885 |
| US-20090240045-A1 | Organic Compounds | CYP3A43, CYP3A4, SLCO1B3 | ADORA2A 2314/4885ADORA3 545/4885ADORA2B 1462/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885ADORA2B 1829/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885ADORA2B 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.